Member Info for CHELSEA7

Thanks Violin Dog, To a better year for both of us, and next news?...............in the very short term, how about a fourth collaboration whilst we wait to hear about trial sites in the U,S,A. Take care,,,,,,,P

Buys 755k Sells 475m

26 Trades...........Aim Share Chat updated

First two buys.................

03/02/2020 09:50 63,533 7.87
03/02/2020 09:41 10,000 7.83
03/02/2020 09:28 47,470 8.4
03/02/2020 08:18 50,000 7.48

How yer doodling, good news?

Now, bid should rise

Morning GF, this is the third attempt at cracking 8p

Up to 220k+ 7.83

7.50/8.50 +16.79%

Just for a few

Wouldn"t surprise me to see the whole trial based in the U.S.A , unless of course we are making progress with other sites here.

Dr Keith Flaherty, Professor of Medicine at Harvard Medical School and Director of Clinical Research at Massachusetts General Hospital Cancer Center, and clinical advisor to Scancell commented:



"Although checkpoint inhibitor combinations have improved outcomes for patients with melanoma, the toxicity of combinations such as ipilimumab plus nivolumab means that there remains a need to develop combinations with other investigational agents such as SCIB1, which have the potential to improve response rates without increasing toxicity."

Buys 761m

Sells 339k

7.50/8,20 +14.60%

Lol, the tipple of my choice, both................made up with that, the jigsaw is falling into place.

Hey, great news, morning, time for tea.

Not neccesarily Ruck objected to your appoinyment weeks ago.

Nothing personal and all that, lol

GN guys

Superb Post

I do!!!

Absolutely Bunsie, good to hear from you. So true what you say, and I am sure many agree.

Best Regards to Filbert and the gals!!!

Ivy, I also think the Plan B was not to allow themselves to be diluted, unless the SP was much higher than todays 6.85 , and why would Scancell so willingly allow Vulpes to hold 30% at a historical low price???

Just my opinion, and would welcome your reply. To raise £8/10m at todays SP would mean issuing 120m odd shares for 6.5p just for example at least. Somehow I can"t see that, Scancell know the cash burn, and we forget the senior members of staff brought in, one specifically for the TCRs. Would Scancell increase their staffing levels and expenditure unless they had more than a clue as to where funding could be coming from?? And would the staff who have joined in the last year be happy to have joined knowing the company is very uncertain of there future??

Just shows they are two very different views, looking at the same information, I will have faith in Vulpes and like your opinion one of us will be right, I hope that is me!!!

GN

Inanaco, enjoyed reading your posts, and totally agree with your comments about Vulpes and dilution. I have always said that IMHO Vulpes would have had a Plan B from the beginning and the further buying at 5.2p leading to a Holdings RNS shows I believe their commitment to Scancell.

Ivy you posted................

""Yes Vulpes involvement and support has been good but they are in profit so have a different perspective.If SCLP go for a £8m raise then if a wider raise which is likely as Vulpes taking a huge chunk may push them over 30% then it is likely ( based on previous history) it will be done at lower levels.""

Don"t really know what you mean by............"".Yes Vulpes involvement and support has been good but they are in profit so have a different perspective""

Well they have a ""paper profit"" the only perspective that is different IMHO is they are here long term, as they have said.

They certainly won"t be in profit if they had to sell in the market, so I believe the further purchase was a sign of confidence to shareholders, they know far better than any of us what is going on behind closed doors, and they will be looking for a big profit, risk/reward, which I believe will come with a commercial deal, whether that be with our collaborators or not. It might well fit in very nicely as I believe any raising will be around September/October, before the accounts are written down, which will near enough cover the years timeline for the collaborators. It was hardly a rampy Interims RNS, but there are real opportunities and inflection points to come, again IMHO

I am with Vulpes here, nobody puts up nigh on £6m without having a PlanB